KADCYLA drug use surveillance
Not Applicable
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000017702
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
The adverse drug reaction incidence rate in 250 examples of safety analysis was 69.60% (174/ 250 example), and the case number was 438, and platelet decreased number 54.40% (136/250 examples), aspartic acid AMINOTORANSUFERAZE increased 31.20 % (78/250 examples), ARANINAMINOTORANSUFERAZE increased 20.00 % (50/250 examples), liver function abnormal 8.00 % (20/250 examples) and nose bleeding 6.80 % (17/250 examples) met main adverse drug reactions (5% or more than of adverse drug reaction incidence rate).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
No criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method